The promise of pharmacoepidemiology in helping clinicians assess drug risk

Circulation

Volumn 128, Issue 7, 2013, Pages 745-748

  Avorn, Jerry ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; DABIGATRAN; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

ADULT; ARTICLE; CASE REPORT; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PATIENT CARE; PHARMACOECONOMICS; PHARMACOEPIDEMIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOPHLEBITIS; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADVERTISING AS TOPIC; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CONFOUNDING FACTORS (EPIDEMIOLOGY); DECISION MAKING; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PHARMACOEPIDEMIOLOGY; PRODUCT SURVEILLANCE, POSTMARKETING; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; THERAPEUTIC EQUIVALENCY; THIOPHENES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WARFARIN;

EID: 84882254681     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.003419     Document Type: Article

References (20)

1. Strom B, Kimmel SE, Hennessy S, eds. Pharmacoepidemiology. 5th ed. West Sussex, UK: Wiley-Blackwell; 2012.
2. Avorn J. In defense of pharmacoepidemiology: Embracing the yin and yang of drug research. N Engl J Med. 2007;357: 2219-2221.
3. Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York, NY: Alfred A. Knopf; 2004.
4. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:480-486.
5. Institute of Medicine. The Future of Drug Safety. Washington, DC: National Academies Press; 2006.
6. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System: A national resource for evidence development. N Engl J Med. 2011;364:498-499.
7. Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflamm Res 1984;6:1-7.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010:363:1877]. N Engl J Med 2009;361:1139-1151.
9. Food and Drug Administration. FDA drug safety communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). http://www. fda.gov/drugs/drugsafety/ ucm282724.htm. Accessed July 23, 2013.
10. Food and Drug Administration. FDA drug safety communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran). http://www. fda.gov/Drugs/DrugSafety/ucm326580. htm. Accessed July 23, 2013.
11. Shireman TI, Mahnken JD, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390-1396.
12. Mini-Sentinel modular program report: Dabigatran, warfarin & GI bleed, intracerebral hemorrhage complete. http://www.minisentinel. org/work-products/Assessments/Mini-Sentinel-Modular-Program-Report-MSY3-MPR31- Part-2-Dabigatran-Warfarin-GIH-ICH.pdf. Accessed July 23, 2013.
13. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272-1274.
14. Rothman KJ, Boice JD. Epidemiologic Analysis with a Programmable Calculator. Bethesda, MD: US Department of Health, Education and Welfare, Public Health Service, National Institutes of Health: 1979. NIH publication No. 79-1649.
15. Farr W. Letter to the Registrar General. In: First Annual Report of the Registrar General. London, UK: HMSO; 1839.
16. Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):41-49.
17. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in "real world" patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol. 2013;61:2264-2273.
18. Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA. 2012;307:1583-1584.
19. Sox H. The Patient-Centered Outcomes Research Institute should focus on highimpact problems that can be solved quickly. Health Aff (Millwood). 2012;31:2176-2182.
20. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). J Am Coll Cardiol. 2011;57:1330-1337.